ACTION

Phase III randomised controlled trial testing the benefit and tolerability of adjuvant chemotherapy in patients aged 70 and over with early stage ER negative or ER weakly positive breast cancer.

Disease site: Breast cancer

Treatment Modality: Chemotherapy

Status: Closed

Trial details

ACTION was an NCRI phase III randomised controlled trial testing the benefit and tolerability of adjuvant chemotherapy in patients aged 70 and over with early stage ER negative or ER weakly positive breast cancer.

The aim of this trial was to address the following hypotheses:

  1. that adjuvant chemotherapy (either AC or EC) will increase the relapse free survival interval in older women with high risk breast cancer, and
  2. that two weekly (accelerated) therapy with GCSF support will not cause undue toxicity in this patient group, compared to the standard three weekly and that both chemotherapy regimens will be acceptable and tolerated in this group of patients

Chief Investigator: Professor Robert Leonard, Charing Cross Hospital, London

ICR-CTSU Scientific Lead: Professor Judith Bliss

Trial management contact: [email protected]

ISRCTN: 41708421

Sponsor: Institute of Cancer Research and Imperial College Healthcare NHS Trust

Funding: Cancer Research UK (CRUK/06/002), AMGEN

Publications and presentations

Leonard R, Ballinger R, Cameron D, et al. Adjuvant chemotherapy in older women (ACTION) study - what did we learn from the pilot phase? Br. J. Cancer 2011;105(9):1260-6.

Red, yellow and blue microscope image of immunofluorescence staining showing extension of prostatic adenocarcinoma into the bladder wall
New drug hope for prostate cancer patients

10/01/25

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in the journal Clinical Cancer Research.
See full story
Left: Plates showing the impact of olaparib on BRCA cancer cells and minimal impact of on healthy cells. (Right) Lynparza, olaparib's brand name, drug packaging. Photo credit: Science Museum Group
ICR welcomes NICE recommendation of olaparib for advanced breast cancer

09/01/25

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for locally advanced or metastatic breast cancer.
See full story